Pharma landing page audits.
Pharma is the most regulated category in paid acquisition. Every above-the-fold has an Important Safety Information footprint, a fair-balance requirement, and a "talk to your doctor" CTA. The audits in this hub grade real branded pharmaceutical ads against their real landing pages on a published four-dimension rubric.
// Category · Pharma
Overview.
Pharma covers branded pharmaceutical advertising from manufacturers and their agencies, plus the unbranded disease-state campaigns that share the same buyer journey. The unifying property for message match: the regulator dictates the page in ways the regulator does not dictate the ad. Important Safety Information (ISI) and fair-balance copy expand the above-the-fold of the page beyond what fits in any ad unit, and the seam between the two is where continuity routinely breaks.
There are also two parallel buyer paths the same account often serves at once. Patient-targeted creative drives one journey: recognition, symptom, talk-to-doctor. HCP-targeted creative drives another: indication, efficacy, prescribing information. When the two land on overlapping page architectures, message match collapses for whichever audience was second in the build order.
What we grade in pharma.
Every audit in this hub runs the same four-dimension rubric documented in the methodology. The substance of a pharma audit is whether the page's above-the-fold pays back the specific promise the ad made, with the ISI and fair-balance copy beside the promise rather than in front of it.
- ↳
Headline echo against the indication or disease state. If the ad targets a specific indication, the H1 should confirm it. Branded pages frequently lead with the brand name only, leaving the indication for the subheadline or a tab below the fold. For an indication-led ad, that is a confirmation failure.
- ↳
Offer continuity for "talk to your doctor." If the ad's CTA is a doctor-discussion guide or savings card, the page's primary above-fold CTA should open the same artifact. Branded pages often default the CTA to "see prescribing information" regardless of which audience clicked.
- ↳
Fair-balance placement that accompanies the benefit. The regulator requires fair balance. The rubric grades whether the safety language sits beside the benefit it qualifies or in a footer the visitor scrolls past. A page that earns a high score is not a page that hides fair balance; it is a page that integrates it.
- ↳
Audience confirmation in the first viewport. Patient and HCP creative belong on separate page experiences. A page that asks the visitor to self-select their audience above the fold passed; a page that defaults to one audience and assumes the other will route themselves failed scent for at least one creative.
Common failure modes.
The mismatches in pharma look different from other categories because the page is co-authored by medical, legal, regulatory, and marketing. None of the failures below are surprising once you see who is in the room.
- ↳
ISI displacing the H1 promise. Required safety language is allowed above the fold; the audit does not penalize its presence. What it penalizes is when ISI swallows the hero and the indication-led promise the ad sold disappears into a sidebar.
- ↳
Brand-name-only H1 on an indication-led click. The ad sells the indication. The page H1 is the brand wordmark. Patients who clicked because of their condition do not recognize the page as theirs until they read the subheadline. The expensive part of the click is already over.
- ↳
Disease-state ad routing to a branded product hero. Disease-state awareness ads carry a different promise than branded ads. Sending both to the same page collapses the awareness-stage visitor into a consideration-stage hero they were not ready to see.
- ↳
HCP-patient creative collision. The same domain serves both audiences with different navigation states. The wrong creative lands the wrong audience on the wrong default. The interstitial that asks "are you a healthcare professional?" arrives after the H1 has already failed scent.
- ↳
"Talk to your doctor" with no doctor-discussion artifact. The CTA exists; the supporting artifact (discussion guide, savings card, find-a-specialist) is two clicks away. The ad implied a tool the visitor could use; the page offers an instruction.
Notes by platform.
Pharma runs paid acquisition across Google, Meta, and a smaller but consistent footprint on LinkedIn for HCP targeting. Platform policy shapes both creative and destination; the patterns below are the ones specific to pharma.
- ↳
Google (paid search). Headline echo dominates. The query carries the indication, the symptom, or the brand. The H1 that leads with the wordmark and buries the indication is the most common failure, especially on long-tail condition queries.
- ↳
Meta. Visual and tonal continuity dominate, inside platform policy. Pharma Meta creative skews to disease-state awareness because of branded-advertising constraints. The mismatch is when an awareness ad lands on a branded product hero with no awareness-stage bridge.
- ↳
LinkedIn. Offer continuity dominates for HCP-targeted creative. An ad promising a clinical resource should land on the resource, not on a patient-facing branded hero. HCP audience confirmation in the first viewport is the load-bearing question.
Audits in this hub.
Cambridge Healthtech Institute
LinkedInThe LinkedIn ads and the summit landing page tell the same story, with the hero headline matching the ads almost word for word, though one ad names a different host city than the page.
healthtech.com/
Centre for Human Drug Research
LinkedInThe CHDR LinkedIn ads promise faster, higher-confidence early-phase trials with advanced data analytics, and the trial-services page broadly confirms a full-service CRO, but the hero headline never echoes the ads' sharpest hooks like data analysis, Phase 1 speed, or FDA-ready deliverables.
chdr.nl/trial-services
Centre for Human Drug Research
LinkedInThe LinkedIn ads sell speed, a 70K-volunteer recruitment database, and FDA-ready deliverables, but the destination page is a generic therapeutic areas overview that never echoes those promises.
chdr.nl/therapeutic-areas
Frequently asked questions.
What counts as a pharma audit?▸
Any audit where a pharmaceutical manufacturer, agency, or brand-aligned third party advertises a branded prescription product or a manufacturer-sponsored disease-state campaign. The umbrella includes patient-targeted DTC pharma, HCP-targeted creative, and unbranded awareness work attributable to a manufacturer. Generics, telehealth-mediated prescribing, and consumer health products are graded under their own hubs.
How do you score Important Safety Information placement?▸
The rubric never penalizes the presence of ISI. It grades the relationship between ISI and the benefit copy the ad sold. ISI beside the benefit, scrollable in the same viewport, is integration. ISI replacing the benefit so that the ad's promise disappears is displacement. Only displacement costs points.
Do you score whether the page meets regulatory requirements?▸
No. PostClickSignal grades message match between the ad and the page. Regulatory adequacy of ISI, fair balance, and indication statements is a different question with its own reviewers. We will note when a regulatory requirement appears to crowd out an ad's promise; we will not assess regulatory compliance.
How do you handle HCP-versus-patient audience confirmation?▸
We treat the interstitial gate as part of the page's above-the-fold. A clear above-fold audience selector that matches the creative's intended audience passes scent. An interstitial that defaults to the wrong audience or assumes the visitor knows which side to choose fails confirmation for the creative that just delivered them.
Do you grade unbranded disease-state advertising?▸
Yes, when the unbranded ad routes to a manufacturer-attributed page. Unbranded creative carries a different promise than branded creative, and the audit grades whether the destination page recognizes the awareness-stage visitor or pushes them straight into branded consideration copy without a bridge.